WSJ News Exclusive | Merck Explores Purchase of Biotech Seagen
Merck MRK -0.32% & Co. is eyeing a purchase of biotech Seagen Inc., SGEN 12.72% according to people familiar with the matter, a move that would beef up the pharmaceutical giant’s cancer-drug portfolio. Talks have been under way for a while, and a deal isn’t imminent, the people said, cautioning that pulling one off could … Read more